AK117/Placebo with Azacitidine

A Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2 Study of AK117/Placebo in Combination With Azacitidine in Patients With Newly Diagnosed Higher-risk Myelodysplastic Syndromes

More Information

Trial Status
Accepting patients
Trial Phase
Phase 2
Enrollment
90 patients (estimated)
Sponsors
Akeso
Tags
Monoclonal Antibody, CD47, Closed Label (Masked), Placebo, Randomization
Trial Type
Treatment
Last Update
4 weeks ago
SparkCures ID
1855
NCT Identifier
NCT06196203

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.